Neurocrine Bio. (NBIX) PT Lowered to $136 at Stifel, Ingrezza's Growth and Sales, and Pipeline Prospects Remain Key Focus for Investors,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 142.16 -1.13 (0.79%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.29 | 52 Week High | $58.46 | |||
| Open | $142.74 | 52 Week Low | $31.25 | |||
| Day High | $143.83 | P/E | N/A | |||
| Day Low | $140.90 | EPS | $-0.69 | |||
| Volume | 623,142 | |||||
